2. Others
  3. Biochemical Assay Reagents
  4. Doranidazole

Doranidazole (PR 350) is a radiosensitizer. Doranidazole increases the radiosensitivity of hypoxic SCCVII cells. Doranidazole significantly enhances radiation-induced growth delay in SCCVII tumors when administered intravenously before tumor irradiation. Doranidazole radiosensitizes tumors to an extent that depends on the tumor's oxygenation status. Doranidazole can be used for the study of lymphoma and hypoxic pancreatic tumors.

For research use only. We do not sell to patients.

Doranidazole

Doranidazole Chemical Structure

CAS No. : 149838-23-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Doranidazole Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Doranidazole (PR 350) is a radiosensitizer. Doranidazole increases the radiosensitivity of hypoxic SCCVII cells. Doranidazole significantly enhances radiation-induced growth delay in SCCVII tumors when administered intravenously before tumor irradiation. Doranidazole radiosensitizes tumors to an extent that depends on the tumor's oxygenation status. Doranidazole can be used for the study of lymphoma and hypoxic pancreatic tumors[1][2][3].

In Vitro

Doranidazole (1 mM) significantly enhances the radiosensitivity of hypoxic SCCVII cells in vitro[1].
Doranidazole (0.1-3.0 mM) can dose-dependently increase radiation-induced micronucleus formation in hypoxic SCCVII cells[1].
Doranidazole (1 mM) enhances radiation-induced apoptosis in Mouse L5178Y lymphoma cells under hypoxic conditions[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Doranidazole Related Antibodies
In Vivo

Doranidazole (50-200 mg/kg, tail vein injection, once) significantly enhances the radiosensitivity of SCCVII tumor cells in mice[1].
Doranidazole (50-200 mg/kg, tail vein injection, once) significantly enhances radiation-induced growth delay of SCCVII tumors in mice and reduces the radiation dose required[1].
Doranidazole (200 mg/kg, tail vein injection, once) can enhance the radiosensitization response of CFPAC-1 tumors in nude mice, but has no radiosensitizing effect on MIA PaCa-2 tumors[1].
Doranidazole (50-200 mg/kg, tail vein injection, once) exhibits a radiosensitizing effect that correlates with tumor oxygenation status; tumors with high hypoxia (such as SCCVII and CFPAC-1) respond better, while well-oxygenated tumors (such as MIA PaCa-2) show no sensitizing effect[1].
Doranidazole (100-250 mg/kg, i.v., once) shows a clear radiosensitizing effect on all four pancreatic cancer cell lines in xenograft nude mice, and the effect is dose-dependent[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C3H/HeN mice were subcutaneously inoculated with SCCVII cells (approximately 2 × 106 cells) in the right hind leg[1].
Dosage: 50 mg/kg, 100 mg/kg, 200 mg/kg
Administration: Tail vein injection, once
Result: The SERs were 1.09-1.36 at 10 min after 50-200 mg/kg injection, indicating caused significant radiosensitization of tumors within 10 min after the drug administration.
The maximum radiosensitization of tumor with a SER of 1.47 occurred 20 min after administration at 200 mg/kg.
Considerable radiosensitization was still evident 40 min after drug administration.
Animal Model: Female C3H/HeN mice were subcutaneously inoculated with SCCVII cells (approximately 2 × 106 cells) in the right hind leg[1].
Dosage: 50 mg/kg, 100 mg/kg, 200 mg/kg
Administration: Tail vein injection, once
Result: An administration of 200 mg/kg alone exerted no effect on the growth of SCCVII tumors.
100 mg/kg was slightly slower than that of the tumors irradiated after saline injection.
The radiation-induced growth delay was further enhanced with 200 mg/kg.
Combining 200 mg/kg with irradiation extended the tumor doubling time to 36 days.
Reduce the required radiation dose.
Animal Model: BALB/c-nu/nu nude mice were subcutaneously inoculated with Human pancreatic tumor cells (CFPAC-1 and MIA Paca-2) in the right hind leg (approximately 5 × 106 cells were inoculated first, and after the tumor grew to 1 cm in diameter, it was cut into small pieces and transplanted into new mice to ensure that the tumors were of uniform size)[1].
Dosage: 200 mg/kg
Administration: Tail vein injection, once
Result: Combined irradiation prolonged the regeneration time of CFPAC-1 tumors to 91 days.
No significant difference in tumor growth delay between the combined irradiation group and the irradiation-alone group in MIA PaCa-2 tumors, which may be related to the better oxygenation status of these tumors.
Animal Model: Four human pancreatic cancer cell lines (SUIT-2, PANC-1, MIA PaCa-2, and BxPC-3) in their exponential growth phase were subcutaneously inoculated at 106 cells per cell in the back of 6-week-old male Balb/c nude mice[3].
Dosage: 100 mg/kg, 250 mg/kg
Administration: I.v., once
Result: At a dose of 100 mg/kg, the SER was 1.15–1.3 (SUIT-2: 1.15, PANC-1: 1.3, MIA PaCa-2: 1.2, BxPC-3: 1.25).
At a dose of 250 mg/kg, the SER increased to 1.35–1.45 (SUIT-2: 1.35, PANC-1: 1.45, MIA PaCa-2: 1.4, BxPC-3: 1.35).
Molecular Weight

247.21

Formula

C8H13N3O6
CAS No.
SMILES

OC[C@H](O)[C@@H](CO)OCN1C([N+]([O-])=O)=NC=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Doranidazole Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Doranidazole149838-23-3PR 350 RP 343PR350PR-350RP343RP 343RP-343Biochemical Assay ReagentsHypoxic cellSensitizerPancreatic tumorOxygenation statusInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Doranidazole
Cat. No.:
HY-105095
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.